Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252228 | 0.84 | CYP19A1 (0.55) | ALDH1A1CYP19A1LMNAHTTTSHR | |
| Ethylene SCHEMBL28777120 | 0.79 | CYP19A1 (0.50) | ALDH1A1CYP19A1LMNAHTTTSHR | |
| SCHEMBL2167915 | 0.74 | ALDH1A1 (0.50) | ALDH1A1HIF1ACYP19A1LMNAHTT | |
| SCHEMBL30919597 | 0.74 | ALDH1A1 (0.50) | ALDH1A1CYP19A1LMNAHTTTSHR | |
| SCHEMBL7666882 | 0.74 | CYP19A1 (0.39) | ALDH1A1CYP19A1LMNAHTTTSHR | |
| SCHEMBL529746 | 0.74 | MAPT (0.50) | HCAR2ALDH1A1CYP19A1LMNAHTT | |
| SCHEMBL488024 | 0.74 | TSHR (0.58) | HCAR2ALDH1A1CYP19A1LMNAHTT | |
| SCHEMBL826834 | 0.74 | ALDH1A1 (0.50) | HCAR2ALDH1A1CYP19A1LMNAHTT | |
| SCHEMBL3607175 | 0.74 | LMNA (0.42) | ALDH1A1CYP19A1LMNAHTTTSHR | |
| SCHEMBL14792479 | 0.74 | CYP19A1 (0.39) | ALDH1A1CYP19A1LMNAHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| EP-4558489-A1 | HETEROARYL DERIVATIVES AS DDRs INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-05-28 | — | — | EP | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-04-11 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024017876-A1 | HETEROARYL DERIVATIVES AS DDRs INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-25 | — | — | WO | disclosed |
| CN-114315595-B | Preparation method of carbon-supported iron-based catalyst and application of intermediate synthesis of anticancer inhibitor of carbon-supported iron-based catalyst | 奥锐特药业股份有限公司 | 2023-12-05 | — | — | CN | disclosed |
| WO-2023098592-A1 | PREPARATION METHOD FOR CARBON-LOADED IRON-BASED CATALYST AND USE THEREOF IN SYNTHESIS OF INTERMEDIATES OF ANTI-CANCER INHIBITORS | 奥锐特药业股份有限公司 | 2023-06-08 | — | — | WO | disclosed |
| CN-114315595-A | Preparation method of carbon-supported iron-based catalyst and synthesis application of anti-cancer inhibitor intermediate thereof | 湖南大学 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021121420-A1 | BENZOPYRAZOLE COMPOUND AND INTERMEDIATE, PREPARATION METHOD, AND APPLICATION THEREOF | 江苏凯迪恩医药科技有限公司 | 2021-06-24 | — | — | WO | disclosed |
| EP-3237385-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-11-01 | — | — | EP | disclosed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | disclosed |
| CN-101516889-B | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones | GLAXO GROUP LTD | 2013-07-31 | — | — | CN | disclosed |
| CN-101516889-A | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones | GLAXO GROUP LTD (GB) | 2009-08-26 | — | — | CN | disclosed |
| CN-1053065-A | AZAOXINDOLE DERIVATIVES | PFIZER (US) | 1991-07-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | HCAR2 2305/4885ALDH1A1 3259/4885HIF1A 2905/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | HCAR2 2305/4885ALDH1A1 3259/4885HIF1A 2905/4885 |
| US-20240116946-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | HCAR2 2305/4885ALDH1A1 3259/4885HIF1A 2905/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | HCAR2 2305/4885ALDH1A1 3259/4885HIF1A 2905/4885 |
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | HCAR2 2305/4885ALDH1A1 3259/4885HIF1A 2905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.